Novartis' drug Zelnorn, used to treat irritable bowel syndrome and severe constipation, may increase risk of cause heart attacks, stroke or death.

Zelnorm manufactured by Novartis Pharmaceuticals Corporation is a selective serotonin receptor agonist. It works by stimulating the release of certain chemicals in the intestines that increase the movement of stools (bowel movement) through the bowel. Zelnorm was approved by the FDA on July 24, 2002. Zelnorm is a prescription drug approved for short term treatment of women with irritable bowel syndrome (IBS). On August 20, 2004, Zelnorm received FDA approval for the treatment of men and women less than 65 years of age with chronic idiopathic constipation.

What are the dangers associated with Zelnorm? On March 30, 2007, the Food and Drug Administration (FDA) recalled Zelnorm, after 29 different clinical trials involving over 18,000 patients demonstrated that users of Zelnorm are at a rate of 700-800 percent greater risk of experiencing heart attacks, strokes and angina. The FDA determined that the risk of heart attack, stroke, serious injury or death far outweighs the benefits of treating a non-life threatening irritable bowel syndrome.

Do not change medications without first consulting your doctor.